Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs3.79 B4.36 B4.52 B5.19 B5.98 B6.89 B7.07 BRecherche et développement1.14 B1.2 B1.32 B1.41 B1.61 B2.05 B2.13 BRésultat d'exploitation-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.79 BTotal des produits hors exploitation1 M-123 M-508 M-358 M-407 M-96 M267 MCharges d'intérêts, nettes des intérêts capitalisés361 M341 M470 M265 M305 M349 M357 MRésultat hors exploitation, hors charges d'intérêts-722 M-682 M-940 M-530 M-391 M-217 M-39 MRevenus/dépenses exceptionnels362 M218 M-38 M-93 M-321 M-228 M-51 MRésultat avant impôts-79 M1.08 B1.14 B1.99 B2.28 B3.38 B3.74 BPart des actionnaires dans le résultat———————Impôts2 M36 M443 M393 M436 M493 M184 MIntérêts ne donnant pas le contrôle / intérêts minoritaires———1 M-8 M-6 M-6 MAutres produits/charges après impôts———————Résultat net avant activités abandonnées-82 M1.04 B698 M1.59 B1.85 B2.89 B3.56 BActivités abandonnées———————Résultat net-82 M1.04 B698 M1.59 B1.85 B2.89 B3.56 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-115 M985 M642 M1.57 B1.85 B2.9 B3.56 BBénéfice par action de base (BPA de base)-0.080.690.451.081.261.962.4Bénéfice par action dilué (BPA dilué)-0.080.690.451.071.251.942.39Nombre moyen d'actions de base en circulation1.42 B1.42 B1.43 B1.45 B1.47 B1.48 B—Nombre d'actions en circulation après dilution1.42 B1.43 B1.44 B1.46 B1.49 B1.49 B—EBITDA1.04 B2.29 B2.78 B3.54 B3.87 B4.98 B5.18 BEBIT-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.79 BCoût des ventes3.46 B3.71 B3.96 B4.34 B5.26 B6.22 B6.36 BAutres coûts des ventes149 M——————Amortissements (flux de trésorerie)1.12 B1.09 B1.14 B1.2 B1.27 B1.37 B1.39 B
Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.